Wisevoter
World

Researchers Identified FSGS in Renal Biopsies

A retrospective study spanning 15 years identified de novo FSGS in 209 renal allograft biopsy samples.

Updated on Oct. 10, 2026 in Stroke

A high-precision microscope lens focused on a glass slide with a biological tissue sample on a clinical steel table.
Researchers identified de novo focal segmental glomerulosclerosis in 209 renal allograft biopsies during a 15-year retrospective study of transplant patients. AI Illustration. Upload story photo >

Researchers analyzed 5,292 renal allograft biopsies collected from January 2011 through February 2026. The study identified de novo focal segmental glomerulosclerosis (FSGS) in 209 of these specimens.

Why it matters

The findings help clarify the occurrence and clinical characteristics of FSGS in transplant recipients. Understanding these trends assists clinicians in managing long-term renal health post-transplantation.

The study found a 3.94% prevalence of FSGS among the 5,292 biopsies examined. In patients identified with the condition, 45.93% showed signs of calcineurin inhibitor-associated toxicity, with a mean patient age of 35.30 years.

The details

Of the 209 cases identified, 69.86% were classified as classical FSGS, and 81.9% occurred in recipients of kidneys from living donors. The mean interval from transplantation to the detection of the condition was 3.46 years, with the cohort predominantly male at 84.21%.

Timeline

  1. The biopsy study period ran from January 2011 through February 2026.

  2. Research findings were presented at an International Congress from September 20-23, 2026.

The Big Picture

This study follows a pattern set by the global research agenda of The Transplantation Society, which prioritizes long-term outcomes for graft survival. The findings mark a continued effort to document histological changes in allografts using data from across the medical community.

Patients who have undergone renal transplantation may consult with their doctors to discuss risks related to long-term immunosuppressive regimens like calcineurin inhibitors. These results help clarify the timeline for potential histological monitoring after a transplant procedure.

The takeaway

Clinicians and patients benefit from long-term monitoring as FSGS can emerge years after a kidney transplant. Consistent biopsy review remains a critical tool for identifying and managing changes in graft health over time.

Further reading

For more information on renal health and related complications, visit the Stroke section.